PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference

About this update from Ptc Therapeutics, Inc.

[{"type":"text","content":"– Strong Sephience™ (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M –","length":95,"tagName":"p","attribs":{}},{"type":"text","content":"– Unaudited 2025 total product and royalty revenue of approximately $823M, exceeding guidance –","length":95,"tagName":"p","attribs":{}},{"type":"text","content":"– 2026 product revenue guidance of $700 – 800M, representing 19 – 36% year-over-year growth –","length":93,"tagName":"p","attribs":{}},{"type":"text","content":"– Strong cash position of approximately $1.94B as of December 31 –","length":66,"tagName":"p","attribs":{}},{"type":"text","content":"WARREN, N.J., Jan. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2026. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at the Company's presentation at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026, at 9:00 a.m. PST / 12:00 p.m. EST.","length":394,"tagName":"p"},{"type":"text","content":""2025 was a highly successful year for PTC, highlighted by the initial regulatory approvals of Sephience and strong start to the global launch," Dr. Klein said. "In 2026, we look forward to continuing the Sephience launch momentum, advancing our innovative earlier-stage programs and moving the company towards becoming cash flow breakeven."","length":361,"tagName":"p"},{"type":"text","content":"Key Corporate Highlights","length":24,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Unaudited 2025 product and royalty revenue of approximately $823.4 million, exceeding guidance, and unaudited 2025 product revenue of approximately $587.8 million","length":162,"tagName":"p"}]},{"val":[{"type":"text","content":"Unaudited Sephience Q4 2025 net revenue of approximately $92.5 million, including $81.6 million in the US and $10.9 million ex-US","length":134,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Unaudited Sephience total net revenue of approximately $112.1 million in 2025 since launch","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"1,134 patient start forms received in the US as of December 31, 2025","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"946 total patients on commer...

More updates from Ptc Therapeutics, Inc.